Yannick Gardin1, Stephanie Lesceu2, Tímea Tatár-Kis3, Vilmos Palya3, John Elattrache4, Marcelo Paniago1, Christophe Cazaban1, Branko Alva1.
1 Ceva Animal Health, Libourne, France, 2 ID Vet, Montpellier, France,
3 Ceva Animal Health, Budapest, Hungary, 4 Ceva Biomune, Lenexa, KS, USA.
In almost all poultry producing countries, Infectious Bursal Disease Virus (IBDV) is regarded as a prevalent and potentially damaging viral pathogen, so that vaccination is routinely used to ensure necessary control. Because of their capacity to overcome maternally derived antibodies, hatchery IBD vaccines of the immune complex or the recombinant rHVT vector types can be systematically administered by injection at the hatchery, either in-ovo or on the first day of age. This possibility has revealed so attractive and advantageous compared to administration of classical live attenuated IBD vaccines at farm, that they have gained strong popularity. However, in this new situation, the use of classical IBD ELISA kits to assess vaccination, monitor immunity or detect possible field infection has yielded difficult to interpret results and given rise to questions and doubts regarding vaccine protection.
To read the full abstract please download it from below.